Protocols

Analysts project a big spike in COPD market as new drugs arrive; Valeant raises $930M in latest asset sale

→  The COPD drug market is expected to grow dramatically over the next decade, hitting $14.1 billion by 2025, according to GlobalData.  It was $9.9 billion in 2015. The growth will be fueled by increased diagnoses as well as new bronchodilator drug classes and anti-eosinophilic biologics.

→  Valeant is selling iNova for $930 million. The company is selling off assets in an attempt to reduce large piles of debt acquired under previous CEO Mike Pearson as he went on a deal-making spree. Pearson was replaced by Joseph Papa last year.

→  CytRx announced it plans to submit a rolling NDA under section 505(b)(2) New Drug Application (NDA) for aldoxorubicin, which has received orphan drug designation, in soft tissue sarcomas (STS). The drug flopped in 2016.

→  Exact Sciences Corporation $EXAS is selling 7m shares of common stock at a public offering price of $35 per share. It’s expected to close June 12.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 34,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->